Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Total Liabilities: 2022-2024

Historic Total Liabilities for Stoke Therapeutics (STOK) over the last 3 years, with Dec 2024 value amounting to $42.5 million.

  • Stoke Therapeutics' Total Liabilities fell 14.78% to $52.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.2 million, marking a year-over-year decrease of 14.78%. This contributed to the annual value of $42.5 million for FY2024, which is 38.16% down from last year.
  • According to the latest figures from FY2024, Stoke Therapeutics' Total Liabilities is $42.5 million, which was down 38.16% from $68.8 million recorded in FY2023.
  • In the past 5 years, Stoke Therapeutics' Total Liabilities registered a high of $71.2 million during FY2022, and its lowest value of $42.5 million during FY2024.
  • For the 3-year period, Stoke Therapeutics' Total Liabilities averaged around $60.8 million, with its median value being $68.8 million (2023).
  • Data for Stoke Therapeutics' Total Liabilities shows a maximum YoY tumbled of 38.16% (in 2024) over the last 5 years.
  • Stoke Therapeutics' Total Liabilities (Yearly) stood at $71.2 million in 2022, then decreased by 3.43% to $68.8 million in 2023, then plummeted by 38.16% to $42.5 million in 2024.